All articles tagged with #makary
The White House authorized plans to remove FDA Commissioner Marty Makary after a year of clashes with HHS leadership, industry groups, and policy fights such as fruit-flavored vaping pods; despite earlier signals of presidential backing, the move gained momentum as replacement candidates emerged and a Senate confirmation would be required for a permanent successor.
FDA Commissioner Marty Makary is under intense political pressure after he initially blocked, then approved, fruit-flavored vapes that use an ID‑verifying age gate—an action Trump pressed him to take. The move, which led to the Wednesday approval of flavors like Blueberry and Mango, has drawn attacks from anti-abortion activists, some administration officials, and vaping advocates, highlighting intra‑White House tensions as Makary juggles Trump’s agenda with staffing and policy controversies.
FDA Commissioner Marty Makary defended the agency’s rejection of Replimune’s melanoma drug candidate in a CNBC interview, saying independent review teams reached the same conclusion and denying corrupt sweetheart deals, while pointing to past approvals like Aduhelm and a Covid-19 booster for young healthy kids as precedents.
FDA Commissioner Marty Makary and Prasad argue that a single pivotal study could suffice for drug approvals, a shift aimed at speeding access but drawing concerns about the robustness of evidence and patient safety.
The FDA faces significant challenges including leadership turnover, internal conflicts, politicization, and low morale, raising concerns about its stability and future direction as it approaches 2026, with uncertainty surrounding Commissioner Marty Makary's role.